Abstract 172P
Background
For pts with HER2-positive advanced/recurrent GC/GEJA in China, treatment options are limited. T-DXd is a HER2-directed antibody-drug conjugate; T-DXd 6.4 mg/kg is approved in the US, EU, Japan, South Korea and Singapore for treatment of locally advanced/metastatic GC/GEJA in adults who received a prior trastuzumab-based regimen. In DESTINY-Gastric01 (DG01), T-DXd showed significant improvements in response rates and overall survival (OS) versus standard therapies in pts from Japan/South Korea with HER2-positive advanced GC/GEJA.
Methods
In this open-label, single-arm, phase 2 trial (NCT04989816), Chinese pts with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+ by central laboratory) advanced GC/GEJA who had received ≥2 prior treatment regimens, including a fluoropyrimidine and a platinum agent, received T-DXd 6.4 mg/kg intravenous infusion once every 3 weeks. Primary endpoint was confirmed objective response rate (ORR) by independent central review (ICR) per RECIST v1.1. Secondary endpoints included investigator-assessed (INV) confirmed ORR, INV duration of response (DOR), INV progression-free survival (PFS), and OS. Safety and tolerability were assessed.
Results
At data cutoff (Jun 16, 2023), 95 pts were enrolled (intent-to-treat [ITT]); 73 pts were confirmed HER2-positive (IHC 3+ or IHC 2+/ISH+; full analysis set [FAS]) by central laboratory. In the FAS, 65.8% of pts were <65 years of age, 72.6% were IHC 3+ and primary tumor location in 30.1% of pts was GEJ. Efficacy and safety data are shown in table.
Conclusions
This primary analysis of T-DXd in Chinese pts with HER2-positive advanced GC/GEJA demonstrated clinically meaningful and durable objective responses, with a manageable safety profile, and is consistent with results from DG01. Table: 172P
| FAS | N=73 |
| Median prior lines of therapy, n (range) | 2 (2–6) |
| Median duration of follow-up, months (Q1, Q3) | 8.0 (6.0, 13.2) |
| ICR confirmed ORR, n (%) | 21 (28.8) |
| INV confirmed ORR, n (%) | 26 (35.6) |
| Median DOR, months (95% confidence interval [CI]) | 7.9 (4.6, 8.8) |
| Median PFS, months (95% CI) | 5.7 (4.0, 6.8) |
| Median OS, months (95% CI) | 10.2 (7.5, 14.3) |
| ITT | N=95 |
| Median T-DXd duration, months (range) | 3.4 (0.4,14.5) |
| Grade (G) ≥3 adverse events (AE), n (%) | 70 (73.7) |
| Discontinued treatment due to AEs, n (%) | 12 (12.6) |
| Discontinued treatment due to COVID-19-associated AEs, n (%) | 5 (5.3) |
| Adjudicated drug-related interstitial lung disease/pneumonitis, n (%) | 3 (3.2) |
| G1 | 2 (2.1) |
| G2 | 1 (1.1) |
| G3–G5 | 0 |
Clinical trial identification
NCT04989816.
Editorial acknowledgement
Under the guidance of the authors and in accordance with Good Publications Practice (GPP), medical writing and editorial support was provided by Robyn Wood, MSc, of Helios Medical Communications, and was funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca, Daiichi Sankyo Daiichi Sankyo.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract